‘We’d like to use the cash’: Big pharma’s preparing to invest income tax reform dollars on big deals

There’s lots of expectation for big-ticket pharmaceutical mergers and acquisitions to lose in 2018. That is in large component because of the tax reform that passed in 2017, which frees up money organizations have actually overseas and lowers the organization taxation rate.
deals – BingNews